World Bulletin/News Desk
U.S. drug regulators gave the nod to a wider use for Roche Holding AG's eye drug Lucentis, approving it for diabetic patients with a vision-robbing eye condition.
Lucentis, made by Roche unit Genentech, is already prescribed for two other eye ailments.
The U.S. Food and Drug Administration's approval makes it available for people with diabetic macular edema, or DME, the most common cause of blindness in people of working age.
The once-monthly injection is now the only FDA-approved drug specifically targeted at DME. But a highly promising candidate from Regeneron Pharmaceuticals Inc may be not too far behind.
DME is a swelling of the retina that occurs in diabetics who suffer from retinopathy, the most common eye disease for people with diabetes. In people affected by DME, damaged blood vessels leak fluid into the retina. This causes blurred vision and severe vision loss.
In 2010, about 3.9 million adults diagnosed with diabetes reported trouble with their vision, the FDA said.
DME has long been treated by laser, which stops blood vessel leakage. Laser treatment can slow vision loss, but rarely leads to vision improvement.
Insulin, which helps people with diabetes control their blood sugar, is also approved for DME, the FDA said, as better-controlled diabetes reduces the likelihood of vision loss.
In clinical trials, Lucentis helped people see at least 15 extra letters on an eye chart. People were also generally able to sustain the vision improvement for at least 24 months. But they have to continue taking the drug to maintain the benefits.
"Today's approval represents a major development for the treatment of people whose vision is impaired by DME," said Dr. Renata Albrecht, director of the FDA's ophthalmology products division.
The FDA approved only the 0.3 mg dose of Lucentis, saying a higher dose that was tested showed no extra benefit in vision.
Genentech said it would sell the 0.3 mg dose for $1,170, compared with the $1,950 it charges for the 0.5 mg dose used to treat other eye conditions.
Lucentis is also approved for wet age-related macular degeneration - the leading cause of blindness among the elderly - and for macular edema following retinal vein occlusion (RVO), a swelling or thickening of the part of the retina responsible for central vision.
For macular degeneration, Lucentis has long competed with Regeneron's drug Eylea as well as with Roche's own cancer drug Avastin, which works in a similar manner but for a fraction of the price.
Avastin is not approved for eye disease. But some doctors have cut the cancer treatment into the small doses needed for an eye injection, which costs only about $50.
A U.S. government study last year found the two drugs to be similarly effective for treating macular degeneration.
However, doctors may be more hesitant to use Avastin for patients with diabetes, said Dr. David Brown, a lead investigator for the Lucentis DME trial, and an associate clinical professor at the Methodist Hospital in Houston.
"The sense in the retina community, for whatever reason, is that Avastin doesn't seem to work as well as Lucentis in DME," Brown said.
Roche unit Genentech has also cautioned that Avastin increased the risk of stroke and heart attack in cancer trials, and noted that diabetics are already at much higher risk for serious heart problems.
Alfonso Calvo Rodriguez of Port Isabel, Texas, has had diabetes for about 13 years. He was diagnosed with DME in 2008. Soon, his eyesight made it difficult to drive.
"I would drive with my binoculars next to me, so I could look at the signs or names of streets," he said.
Rodriguez, 57, was forced to have laser surgery to remove blood from his eyes after hemorrhages. His doctor recommended that he enroll in the Lucentis clinical trial at the Methodist Hospital in Houston.
He has been getting monthly injections of the drug for over three years, and said he now needs only glasses to drive.
"I can do just about anything," he said. "I can read. I can work on my computer. I can drive perfectly fine and see the signs on the streets. I'm sure I'd be blind if I didn't have the injections."
The FDA said about 34 percent to 45 percent of those treated with the 0.3 mg dose of Lucentis in clinical trials had vision improvement, compared with 12 percent to 18 percent of those getting no injection.
Common side effects included eye pain, increased pressure inside the eye, and bleeding of the conjunctiva, the tissue that lines the inside of the eyelids and covers the white part of the eye.
The weeklong campaign will target seven of South Sudan's ten states.
The latest cases bring the total number of confirmed cases in the kingdom to 272, of whom 81 have died.
In a survey conducted last year, most water analyzed was deemed to be "very poor" or "relatively poor" in standard and cannot be used for drinking purposes.
Poaching rhinos for their horns is a growing problem in South Africa and a lucrative business for organised criminal networks but it is unusual for thieves to target stock piles.
The 17 new cases, announced late on Monday on the Health Ministry website, bring the total number of Saudi infections to 261, of whom 81 have died
The amendments, now in their fourth draft, are expected to enshrine environmental protection as the overriding priority of the Chinese government
In 2008, the Zambian government banned smoking in public places, relying on state police to enforce the prohibition.
Saudi Arabia has reported 244 cases of MERS since the disease was identified in 2012, of which 79 have been fatal.
China is aiming to make energy production and consumption more ecological to fight smog, siad the Chinese Premier.
MERS has no vaccine or anti-viral treatment, but international and Saudi health authorities say the disease, which originated in camels, does not transmit easily between people and may simply die out
Blamed on the uncontrolled and overuse of farm chemicals, the level of contamination has raised a number of health concerns, with certain villages already showing higher rates of cancer than the national average.
The deputy minister called on South Sudanese farmers in states that have not been hit by famine to cultivate their farmlands to avoid exacerbating the crisis in the country.
Researchers determined that while the Guinean form of the Ebola virus (EBOV) showed a 97 percent similarity to the Zaire strain, the disease was not introduced from Central Africa.
Pakistan's army will join campaign to eradicate polio.
Instead of testing one drug at a time, a novel lung cancer study announced will allow British researchers to test up to 14 drugs from AstraZeneca and Pfizer at the same time within one trial
Australian Immigration Minister Scott Morrison's office said that medical officers at the centre had confirmed three cases of the potentially fatal tropical disease, which is transmitted by mosquitoes